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Upon delivery into gastric epithelial cells, Helicobacter pylori cytotoxin-associated gene A (CagA)
binds and deregulates cellular proteins such as Src homology 2 domain-containing protein tyro-
sine phosphatase 2 and partitioning-defective 1 (PAR1), thereby acting as an epigenetic oncopro-
tein that promotes early phases of gastric cancer development. To elucidate the spatial and
temporal contribution of CagA to carcinogenesis, it is crucial to know the stability of CagA in host
cells. Here we show that the biological half-life of CagA is about 200 min in gastric epithelial cells.
Furthermore, deletion of the PAR1-binding sequence accelerates CagA degradation. Thus, CagA is
a relatively short half-life protein whose stability may be modulated through complex formation
with PAR1.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Chronic infection with cytotoxin-associated gene A (cagA)-posi-
tive Helicobacter pylori strains is critically involved in the devel-
opment of gastric adenocarcinoma [1]. The cagA gene-encoded
CagA protein is delivered into H. pylori-attached gastric epithelial
cells via the bacterial type IV secretion system [2–4]. Delivered
CagA localizes to the inner surface of the plasma membrane,
where it is tyrosine-phosphorylated at the C-terminal Glu-Pro-
Ile-Tyr-Ala (EPIYA) motifs by host cell kinases [5,6]. Tyrosine-
phosphorylated CagA acquires the ability to bind and aberrantly
activate Src homology 2 (SH2) domain-containing protein tyro-
sine phosphatase 2 (SHP-2), a cytoplasmic phosphatase known
to act as a bona ﬁde oncoprotein in human malignancies, via
the phosphotyrosine–SH2 domain interaction [7,8]. CagA also
binds to partitioning-defective 1 (PAR1)/microtubule afﬁnity-reg-chemical Societies. Published by E
; CagA-N, N-terminal CagA;
IYA, Glu-Pro-Ile-Tyr-Ala; HA,
2, Src homology 2 domain-
osphorylation-resistant; WT,
cular Oncology, Institute for
shi-7, Kita-ku, Sapporo 060-
akeyama).ulating kinase (MARK), a master regulator of cell polarity, in a
tyrosine phosphorylation-independent manner [9]. The CagA–
PAR1 interaction is mediated by the C-terminal 16-amino-acid
stretch of CagA, termed the CagA-multimerization (CM) sequence
[10], and by the 27-amino-acid stretch present in the C-terminal
of the PAR1 kinase domain. Upon complex formation, CagA
inhibits PAR1 kinase and thereby causes junctional and polarity
defects in polarized epithelial cells [9].
Consistent with the tumor-relevant biological activities of
CagA demonstrated in in vitro studies [11], systemic expression
of CagA in cagA-transgenic mice induced gastrointestinal and
hematological malignancies [12]. This ﬁnding conﬁrms the onco-
genic potential of the bacterial protein in mammals. A unique
feature of CagA is that it acts as an ‘‘epigenetic oncoprotein”,
which is not encoded by a host gene but promotes early phases
of gastric carcinogenesis upon delivery from cagA-positive H. py-
lori. This in turn indicates that cells predisposed to transforma-
tion require continuous or intermittent exposure to CagA in
order to maintain a premalignant phenotype until they acquire
genetic alterations that compensate CagA functions underlying
the transformed phenotype. To elucidate the dynamic interaction
of delivered CagA with target molecules that underlies cell trans-
formation, it is crucial to know the stability of CagA protein
delivered into host cells. As an initial step, we determined in this
work the biological half-life of CagA in gastric epithelial cells andlsevier B.V. All rights reserved.
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CagA.
2. Materials and methods
2.1. Plasmid constructs
Mammalian expression vectors for hemagglutinin (HA)-tagged
wild-type CagA (WT-CagA) and its mutants have been describedFig. 1. Stability of infected or transfected H. pylori CagA proteins in gastric epithelial cells
(Left) Equal amounts (50 mg) of total protein extracts were resolved by SDS–PAGE and i
luminescence image analysis of tyrosine-phosphorylated CagA protein bands. Relative am
was set as 1. Values are given as mean ± S.D. (n = 3). (B) AGS cells transfected with WT-Ca
amounts (50 mg) of total cell extracts were resolved by SDS–PAGE and immunoblotted
image analysis of each CagA protein bands. Relative amount of WT-CagA or PR-CagA at
(n = 3). (C) AGS cells transfected with WT-CagA vector were treated with various conce
resolved by SDS–PAGE and evaluated for CagA and pRB by immunoblotting.previously [10,13,14]. The N-terminal CagA fragment (CagA-N)
was made by deletion of residues 868–1247.
2.2. Transfection and infection
AGS human gastric epithelial cells were transfected with
expression vectors using Lipofectamine 2000 (Invitrogen) or in-
fected with H. pylori NCTC11637 strain at a multiplicity of infection
(MOI) of 100 for 4 h.. (A) AGS cells infected by H. pyloriwere treated with antibiotics for indicated times.
mmunoblotted with indicated antibodies. (Right) Quantitative graph obtained by a
ount of tyrosine-phosphorylated CagA at 1 h after the onset of antibiotic treatment
gA or PR-CagA vector were treated with 25 mM CHX for indicated times. (Left) Equal
with indicated antibodies. (Right) Quantitative graph obtained by a luminescence
1 h after the onset of CHX treatment was set as 1. Values are given as mean ± S.D.
ntrations of MG132 for 8 h. Equal amounts (50 mg) of total protein extracts were
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Anti-HA (3F10) and anti-actin (C11) antibodies were obtained
from Santa-Cruz Biotechnology. Anti-phosphotyrosine antibody
(4G10) was from Upstate Biotechnology. Anti-CagA antibody was
from AUSTRAL Biologicals.
2.4. Immunoblotting and immunocytochemistry
Immunoblot analysis was described previously [13]. Intensities
of protein bands were quantitated by a lumino-image analyzer
(LAS-1000, Fujiﬁlm). The half-reduction time of CagA was calcu-
lated according to the one-phase exponential decay formula [15].
Immunocytochemical analysis was described [7]. Images were ac-
quired using a con-focal microscope system (Leica Microsystems).
3. Results and discussion
To estimate the biological half-life of the CagA protein delivered
by H. pylori, AGS gastric epithelial cells were infected with H. pylori
NCTC11637 strain carrying ABCCC-type CagA [7]. After 4 h of infec-
tion, the cells were treated with 100 U/ml of penicillin and 100 lg/
ml of streptomycin and harvested at indicated time points. Protein
extracts prepared were subjected to immunoblotting analysis with
indicated antibodies (Fig. 1A). Since H. pylori was not completely
eliminated from the AGS cells in the infection experiment, CagA
proteins were extracted not only from infected AGS cells but also
from H. pylori upon lysis. Accordingly, we performed kinetic anal-
ysis for the levels of tyrosine-phosphorylated CagA because CagA is
tyrosine-phosphorylated by Src or Abl kinase exclusively in the
host cells. From time-course analysis of intracellular degradation,
half-reduction time of tyrosine-phosphorylated CagA, which is
thought to represent the biologically full-active CagA, was esti-
mated to be 148 min (Fig. 1A). Assuming that CagA stability is
independent of tyrosine phosphorylation, the result indicates that
H. pylori-delivered CagA is a relatively short half-life protein in host
gastric epithelial cells.
We next investigated the biological half-life of the CagA protein
ectopically expressed in gastric epithelial cells by transfection. To
do so, AGS cells were transiently transfected with an expression
vector for WT-CagA (ABCCC-type) derived from H. pylori
NCTC11637 strain. At 24 h after transfection, cells were treated
with 25 lg/ml of cycloheximide (CHX) to prevent protein synthe-
sis. Cells were then harvested at indicated time points and lysatesFig. 2. Stability of CagA mutants in gastric epithelial cells. AGS cells transfected with CagA
Schematic view of WT-CagA, CagA-N and CagA-DEPIYA (upper). Equal amounts (50 m
indicated antibodies (lower). (Right) Quantitative graph obtained by a luminescence imag
type or mutant, at 1 h after the onset of CHX treatment was set as 1. Data for WT-CagAwere subjected to immunoblotting with the indicated antibodies
(Fig. 1B). Quantitation of CagA proteins at each time point revealed
that the half-reduction times of total CagA and tyrosine-phosphor-
ylated CagA were 191 min and 210 min, respectively (Fig. 1B). The
results indicated that the stability of CagA in host cells is not inﬂu-
enced by tyrosine phosphorylation of CagA. This conclusion was
further supported by the observation that the biological half-life
of phosphorylation-resistant CagA (PR-CagA) (195 min) was al-
most identical to that of WT-CagA (191 min) in the transfection
experiment. The observed difference in the biological half-life of
infected CagA (148 min) and that of transfected CagA (191 min)
may reﬂect difference in intracellular degradation process between
H. pylori-injected CagA and cDNA-directed CagA. Alternatively, the
difference may be due to the different experimental methods em-
ployed to determine half-reduction times for the two proteins. In-
deed, CHX cannot be used to determine protein half-life in the case
of an infection experiment because CagA is delivered by H. pylori.
However, subsequent statistical analysis revealed that there was
no signiﬁcant difference in the biological half-life between H. py-
lori-delivered CagA (mean ± S.D. = 148 ± 24 min) and cDNA-direc-
ted CagA (mean ± S.D. = 191 ± 61 min) (P < 0.05, n = 3, Student’s t-
test). From these observations, we concluded that the CagA pro-
tein, either infected or transfected, is a relatively short half-life
protein in gastric epithelial cells, having a biological half-life of
about 200 min.
We also wanted to know if CagA degradation is mediated by the
26S proteasome. To this end, we compared the amounts of CagA in
AGS cells in the presence and absence of the proteasome inhibitor
MG132 for 8 h and found that MG132 did not inﬂuence CagA pro-
tein levels (Fig. 1C). Since MG132 at the concentrations of more
than 5 lg/ml inhibited cell cycle progression as determined by
accumulation of the hypophosphorylated form of pRB, MG132
was actively inhibiting proteasome function at these concentra-
tions. Thus, CagA degradation is independent of the 26S
proteasome.
To elucidate the structural basis underlying CagA stability, we
next performed time-course analysis of intracellular degradation
of the N-terminal two thirds of CagA (CagA-N) in AGS cells. As pre-
sented in Fig. 2, inhibition of protein synthesis by CHX showed that
half-reduction time of CagA-N was 74 min. The result of the exper-
iment indicated the possibility that the C-terminal one third of
CagA, to which both SHP-2 and PAR1 bind, stabilizes the CagA pro-
tein. To further pursue this possibility, we made use of another-N or CagA-DEPIYA vector were treated with 25 mM CHX for indicated times. (Left)
g) of total protein extracts were resolved by SDS–PAGE and immunoblotted with
e analysis of each CagA protein bands. Relative amount of CagA protein, either wild-
was same as that shown in Fig. 1. Values are given as mean ± S.D. (n = 3).
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(residues 868–1086) was internally deleted. Notably, the CagA-
DEPIYA mutant bound neither SHP-2 nor PAR1 [9,14]. Results of ki-
netic study of CagA-DEPIYA degradation revealed that the half-
degradation time of CagA-DEPIYA was almost the same as that of
CagA-N (71 min) (Fig. 2), further supporting the idea that complex
formation of CagA with cellular protein stabilizes CagA.
The above-described observations indicated the importance of
the EPIYA-repeat region in the protein stability of CagA. Notably,
CagA is known for the presence of structural polymorphism in
the EPIYA-repeat region and, based on the structural difference,
can be subdivided into two geographically distinct subspecies,
Western CagA and East Asian CagA [8,13]. It has also been reported
that East Asian CagA binds SHP-2 more strongly than Western
CagA does. Accordingly, we wanted to compare the stability of East
Asian CagA and that of Western CagA. To do so, we expressed
CagA-ABD, in which the EPIYA-repeat region of WT-CagA
(ABCCC-typeWestern CagA) was replaced by the corresponding re-
gion of East Asian CagA from H. pylori F32 strain [13]. Expression of
CagA-ABD in AGS cells by transfection revealed that half-degrada-
tion time of CagA-ABD was 166 min (Fig. 3A). Although the time
was slightly shorter than that of Western CagA, there was no sta-
tistically signiﬁcant difference for the half-life between Western
CagA and East Asian CagA.
Involvement of the EPIYA-repeat region in the stabilization of
CagA in cells indicated that interaction of CagA with cellular tar-
gets increases the stability of the bacterial protein. In this regard,
however, the ﬁnding that PR-CagA, which cannot bind SHP-2 [7],Fig. 3. Role of CM sequence in CagA stability. (A) AGS cells transfected with CagA-ABD
Schematic view of CagA-ABD and CagA-ABDDCM (upper). Equal amounts (50 mg) of tot
antibodies (lower). (Right) Quantitative graph obtained by a luminescence image analysis
onset of CHX treatment was set as 1. Values are given as mean ± S.D. (n = 3). (B) Subce
ABDDCM vector. At 24 h after transfection, cells were stained with an anti-HA-antibody (
2-phenylindole (DAPI, blue) to visualize the nucleus.has the same biological half-life as that of WT-CagA indicates that
SHP-2 is not involved in CagA stabilization. This in turn raises the
possibility that another CagA interactor, PAR1, is involved in the
stabilization of CagA. To pursue this possibility further, we exam-
ined a CagA mutant, CagA-ABDDCM, in which the 16-amino-acid
PAR1-binding CM sequence was speciﬁcally deleted from CagA-
ABD [9,14]. Inhibition of protein synthesis by CHX showed that
the half-life of CagA-ABDDCM was 107 min in AGS cells (Fig. 3A).
Staining of the cells with an anti-CagA antibody revealed that both
CagA-ABD and CagA-ABDDCM were distributed to the plasma
membrane (Fig. 3B), indicating that deletion of the CM sequence
does not perturb subcellular localization of CagA, which could af-
fect protein stability. These observations indicate that the CM se-
quence plays an important role in the stabilization of CagA and
suggest that interaction of CagA with PAR1 increases CagA stability
in gastric epithelial cells.
Our present work reveals that CagA is a relatively short half-life
protein. This in turn indicates that, to maintain pathophysiological
actions of CagA in host cells, H. pylorimust frequently deliver CagA
into the cells. Accordingly, a critical question to be solved is the
lowest level of CagA concentration that is required for the practical
CagA action in host cells. Given the rapid turnover of CagA, it is
possible that low levels of CagA are sufﬁcient for perturbation of
cell functions. The possibility is supported by the observation that
CagA transgenic mice develop tumors despite low levels of CagA
expression in vivo [12].
Relatively rapid turnover of CagA in host cells is also consistent
with the fact that development of gastric cancer requires a longor CagA-ABDDCM vector were treated with 25 mM CHX for indicated times. (Left)
al protein extracts were resolved by SDS–PAGE and immunoblotted with indicated
of each CagA bands. Relative amount of CagA-ABD or CagA-ABDDCM at 1 h after the
llular localization of CagA mutants. AGS cells transfected with CagA-ABD or CagA-
red), which recognizes transfected CagA. Cells were also stained with 4,6-diaminino-
2418 S. Ishikawa et al. / FEBS Letters 583 (2009) 2414–2418incubation time, lasting several decades. This indicates that the
progression of multistep gastric carcinogenesis is a slow and inef-
ﬁcient process, most probably due to the difﬁculty in keeping the
oncogenic actions of CagA in effect for a certain period, during
which host genetic alterations that can compensate the oncogenic
action of CagA must occur.
CagA degradation is mediated by a mechanism independent of
26S proteasome. Interestingly, CagA lacking the PAR-binding CM
sequence exhibits accelerated degradation, indicating that com-
plex formation of CagA with PAR1 stabilizes CagA. Because CagA–
PAR1 interaction stimulates complex formation between CagA
and SHP-2 phosphatase [9], stabilization of CagA by PAR1 may
potentiate the ability of CagA to bind and aberrantly activate
SHP-2, a bona ﬁde oncoprotein deregulation of which is involved
in the development of a variety of human malignancies [11]. De-
tailed structural analysis of the CagA–PAR1 interaction may lead
to the development of a small compound that competitively inhib-
its CagA–PAR1 interaction and thereby promotes CagA degradation
while inhibiting CagA function. Such a compound may be applica-
ble for clinical therapeutics of cagA-positive H. pylori-associated
gastric carcinoma.
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